Jobs
-
A study published online in CHEST on June 25, 2015 finds that discontinuing inhaled corticosteroids for COPD patients reduced the risk of pneumonia by 37%, with the greatest reduction in risk associated with stopping inhaled… Read more . . .
-
Teva Pharmaceutical’s DuoResp Spiromax multidose DPI has won a Silver award at the 2015 Medical Design Excellence Awards (MDEA), with Gerresheimer receiving credit as a supplier. DuoResp Spiromax received European marketing authorization in April 2014.… Read more . . .
-
According to Boehringer Ingelheim, the United Kingdom, Croatia, Slovakia, Denmark, Norway, Ireland, Austria, Romania and Spain have approved the Spiolto Respimat tiotropium/olodaterol SMI for the treatment of COPD. BI recently announced the launch of the… Read more . . .
-
For podium presentations, submit 200-word summary by August 15, 2015 at http://www.rddonline.com/rdd/speaker_reg.php?id=12 For information on topics, see http://www.rddonline.com/rdd/rdd.php?id=12&sid=3 For posters, submit abstract by January 8, 2016. See http://www.rddonline.com/rdd/rdd.php?id=12&sid=4 for further information. Nominations for the Charles… Read more . . .
-
The Canadian Agency for Drugs and Technology in Health (CADTH) has issued a call for patient input regarding GSK’s Breo Ellipta fluticasone furoate/vilanterol DPI for the treatment of asthma. According to the announcement, the agency… Read more . . .
-
The Israeli Patent Office has issued Patent No. 193318, “System for Pulmonary Delivery of Alpha-1 Proteinase Inhibitor,” to Kamada and PARI Pharma, Kamada has announced. The patent relates to delivery of Kamada’s inhaled alpha-1 proteinase… Read more . . .
-
Boehringer Ingelheim Pharmaceuticals has announced the availability of the Stiolto Respimat tiotropium bromide/olodaterol soft mist inhaler in the United States. Stiolto Respimat was approved by the FDA for the treatment of COPD in May 2015.… Read more . . .
-
Current AstraZeneca Vice President Respiratory, Inflammation & Autoimmunity James Ward-Lilley will become CEO of Vectura Group as of October 1 2015. Vectura had previously announced that its current CEO, Chris Blackwell, will be stepping down… Read more . . .
-
OptiNose has announced positive results from the 24-week Phase 3 trial of OPN-375, an intranasal fluticasone product for the treatment for nasal polyps based on the company’s Bi-Directional Breath-Powered delivery system. The study showed statistically… Read more . . .
-
Copley Scientific has announced the publication of a brochure titled “Quality Solutions for Inhaler Testing, 2015 Edition” which includes a guide for testing of novel and generic OINDPS. The brochure includes an introduction to various… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA